Standard BioTools Inc. (LAB)

NasdaqGS: LAB · Real-Time Price · USD

0.71

-0.04 (-5.33%)

At close: Aug 14, 2026, 3:59 PM

0.72

+1.07%

After-hours: 7:34 PM

Statistics

Share Statistics

Standard BioTools has 392.58M shares outstanding. The shares have a market value of 279.67M.

Shares Outstanding	392.58M
Shares Change (YoY)	8.21%
Shares Change (QoQ)	0.69%
Owned by Institutions (%)	n/a
Shares Floating	n/a
Failed to Deliver (FTD) Shares	31,325
FTD / Avg. Volume	n/a

Short Selling Information

Short Interest	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Valuation Ratios

PE Ratio	n/a
Forward PE	-71.24
PS Ratio	3.31
Forward PS	3.41
PB Ratio	0.52
P/FCF Ratio	-3.39
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	0.05
Debt / EBITDA	-0.42
Debt / FCF	-0.34
Interest Coverage	-2775.42

Financial Efficiency

Return on Equity is 0%, and return on invested capital is -12.7%.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	-12.7%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count
Asset Turnover	0.13
Inventory Turnover	2.45

Taxes

Income Tax	-37.05M
Effective Tax Rate	40.72%

Stock Price Statistics

The stock price has increased by null% in the past year.

Beta
52-Week Price Change	n/a
50-Day Moving Average	0.85
200-Day Moving Average	1.1
Relative Strength Index (RSI)	41.67
Average Volume (20 Days)	n/a

Income Statement

In the last 12 months, Standard BioTools had revenue of 84.6M and earned 84.91M in profits. Earnings per share was 0.22.

Revenue	84.6M
Gross Profit	42.71M
Operating Income	-62.64M
Net Income	84.91M
EBITDA	-66.67M
EBIT	-72.16M
Earnings Per Share (EPS)	0.22

Full Income Statement

Balance Sheet

Standard BioTools has 270.03M in cash on the balance sheet. Total assets are 627.22M, and total liabilities are 28.09M.

Cash & Cash Equivalents	270.03M
Total Debt	28.09M
Net Cash	241.94M
Retained Earnings	-1.16B
Total Assets	627.22M
Working Capital	460.06M

Full Balance Sheet

Cash Flow

Standard BioTools's operating cash flow was -80.3M over the trailing twelve months.

Operating Cash Flow	-80.3M
Capital Expenditures	-2.28M
Free Cash Flow	-82.58M
FCF Per Share	-0.21

Full Cash Flow Statement

Margins

Standard BioTools's gross profit margin was 50.49%, while its operating and net profit margins were -74.04% and 100.37%, respectively.

Gross Margin	50.49%
Operating Margin	-74.04%
Pretax Margin	-107.55%
Profit Margin	100.37%
EBITDA Margin	-78.81%
EBIT Margin	-85.3%
FCF Margin	-97.61%

Dividends & Yields

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	30.88%
FCF Yield	-29.53%

Dividend Details

Analyst Forecast

According to 1 stock analysts, the average 12-month price target for Standard BioTools is $1.35. The average analyst rating is "Hold".

Price Target	$1.35
Price Target Difference	89.5%
Analyst Consensus	Hold
Analyst Count	1

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the fair value of a stock. The Graham Number estimates a fair value of $2.61, representing a potential upside of 266.37%.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	2.61
Graham Upside	266.37%

Scores

Altman Z-Score	-0.03
Piotroski F-Score	4